151
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias

, , , , , , & show all
Pages 2338-2342 | Received 15 Jun 2023, Accepted 19 Sep 2023, Published online: 04 Oct 2023

References

  • Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. doi:10.1182/blood.2022015850
  • Khoury JD, Solary E, Abla Q, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
  • Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107(2):101–107. doi:10.1159/000046639
  • Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41(4):461–476. doi:10.1016/j.humpath.2009.11.003
  • Li T, Zhang G, Zhang X, et al. The 8p11 myeloproliferative syndrome: genotypic and phenotypic classification and targeted therapy. Front Oncol. 2022;12:1015792. doi:10.3389/fonc.2022.1015792
  • Shimamoto A, Kitao S, Ichikawa K, et al. A unique human gene that spans over 230 kb in the human chromosome 8p11-12 and codes multiple family proteins sharing RNA-binding motifs. Proc Natl Acad Sci U S A. 1996;93(20):10913–10917. doi:10.1073/pnas.93.20.10913
  • Sun Y, Ding L, Zhang H, et al. Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMS. Nucleic Acids Res. 2006;34(21):6314–6326. doi:10.1093/nar/gkl914
  • Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human core blood-derived CD133+ cells. Stem Cells. 2006;24(3):631–641. doi:10.1634/stemcells.2005-0185
  • Stengel A, Shahswar R, Haferlach T, et al. Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. Blood Adv. 2020;4(21):5393–5401. doi:10.1182/bloodadvances.2020003007
  • Strati P, Tang G, Duose DY, et al. Myeloid/lymphoid neoplasm with FGFR1 rearrangement. Leuk Lymphoma. 2018;59(7):1672–1676. doi:10.1080/10428194.2017.1397663
  • Hussein S, Gill KZ, Sireci AN, et al. Aberrant T-cell antigen expression in B-lymphoblastic leukemia. Br J Haematol. 2011;155(4):449–456. doi:10.1111/j.1365-2141.2011.08870.x
  • Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086–1093. doi:10.1038/nm.2415
  • Gentles AJ, Plevritis SK, Majeti R, et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010;304(24):2706–2715. doi:10.1001/jama.2010.1862
  • Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012;30(25):3109–3118. doi:10.1200/JCO.2011.40.6652
  • Gotlib J, Kiladjian J-J, Vannucchi A, et al. A phase 2 study of Pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasm (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1). Blood. 2021;138(Suppl 1):385–385. doi:10.1182/blood-2021-148103

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.